Phase II study of the combination of Lenalidomide and Alemtuzumab as consolidation in patients who responded to a previus chemotherapeutic regimen administered for relapsed or refractory Chronic Lymphocytic Leukemia (CLL)
Latest Information Update: 25 Jun 2013
At a glance
- Drugs Alemtuzumab (Primary) ; Lenalidomide (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- 16 Apr 2013 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.
- 13 Oct 2011 New trial record